Company: HROW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001641172-25-000925
Chunk: 509

Company: HARROW, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 2
Chunk 509
---
daq Stock Market LLC under the symbol “HROW” and the Notes are listed on The Nasdaq Stock Market LLC under the symbols
“HROWL” and “HROWM.”

 53 

Holders

As of February 28, 2025, there
were approximately 57 stockholders of record (excluding an indeterminable number of stockholders whose shares are held in street or “nominee”
name) of our common stock.

Dividends

We have not paid any dividends
on our common stock since our inception and do not expect to pay dividends on our common stock in the foreseeable future.

Purchase of Equity Securities

We did not purchase any of our
equity securities during the fourth quarter of 2024.

Recent Sales of Unregistered Securities 

None.

ITEM 6. [RESERVED]

 54 

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and
analysis of our financial condition and results of operations should be read in conjunction with the consolidated financial statements
and the related notes contained in this Annual Report on Form 10-K (this “Annual Report”). Our consolidated financial statements
have been prepared and, unless otherwise stated, the information derived therefrom as presented in this discussion and analysis is presented,
in accordance with accounting principles generally accepted in the U.S. (GAAP). In addition to historical information, the following
discussion contains forward-looking statements based upon our current views, expectations and assumptions that are subject to risks and
uncertainties. Actual results may differ substantially from those expressed or implied by any forward-looking statements due to a number
of factors, including, among others, the risks described in the “Risk Factors” section and elsewhere in this Annual Report.

As used in this discussion
and analysis, unless the context indicates otherwise, the terms the “Company,” “Harrow” “we,” “us”
and “our” refer to Harrow, Inc. and its consolidated subsidiaries, including Imprimis RxNJ, LLC, Imprimis NJOF, LLC, ImprimisRx,
LLC, Harrow IP, LLC and Harrow Eye, LLC.

Overview 

We are a leading eyecare pharmaceutical
company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the U.S. market.
We help U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription